Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension

Journal of the American Society of Hypertension

Volumn 8, Issue 12, 2014, Pages 872-881

  Oxlund, Christina S ^a   Buhl, Kristian B ^b   Jacobsen, Ib A ^a   Hansen, Mie R ^b   Gram, Jeppe ^c   Henriksen, Jan Erik ^a   Schousboe, Karoline ^d   Tarnow, Lise ^e   Jensen, Boye L ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ESBJERG HOSPITAL   (Denmark)

^d LILLEBAELT HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

Albuminuria; epithelial sodium channel; plasmin; type 2 diabetes mellitus; urinary plasminogen activator

Indexed keywords

AMILORIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE; UROKINASE; ANTIHYPERTENSIVE AGENT; CREATININE; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; PLASMINOGEN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERKALEMIA; HYPOTENSION; INTERVENTION STUDY; INTESTINE INFECTION; KIDNEY FUNCTION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT COMPLIANCE; PLASMINOGEN ACTIVATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESISTANT HYPERTENSION; UPPER GASTROINTESTINAL BLEEDING; URINALYSIS; ALBUMINURIA; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; HYPERTENSION; KIDNEY FUNCTION TEST; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE; WESTERN BLOTTING;

ADULT; AGED; ALBUMINURIA; AMILORIDE; ANTIHYPERTENSIVE AGENTS; BLOTTING, WESTERN; CREATININE; DIABETES MELLITUS, TYPE 2; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPITHELIAL SODIUM CHANNEL BLOCKERS; FEMALE; HUMANS; HYPERTENSION; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PLASMINOGEN; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84915809448     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2014.09.019     Document Type: Article

References (31)

1. G. Reboldi, G. Gentile, V.M. Manfreda, F. Angeli, and P. Verdecchia Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes Curr Cardiol Rep 14 2012 89 96
2. S. Vijan, and R.A. Hayward Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care Ann Intern Med 138 2003 593 602
3. T. Sehestedt, T.W. Hansen, Y. Li, T. Richart, J. Boggia, and M. Kikuya Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations Hypertens Res 34 2011 714 721
4. Y. Wang, A. Yuan, and C. Yu Correlation between microalbuminuria and cardiovascular events Int J Clin Exp Med 6 2013 973 978
5. C.C. Gonzaga, and D.A. Calhoun 2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice? Pol Arch Med Wewn 118 2008 396 397
6. E. Hommel, E.R. Mathiesen, J. Giese, M.D. Nielsen, H.J. Schutten, and H.H. Parving On the pathogenesis of arterial blood pressure elevation early in the course of diabetic nephropathy Scand J Clin Lab Invest 49 1989 537 544
7. P. Svenningsen, O. Skott, and B.L. Jensen Proteinuric diseases with sodium retention: is plasmin the link? Clin Exp Pharmacol Physiol 39 2012 117 124
8. P. Svenningsen, C. Bistrup, U.G. Friis, M. Bertog, S. Haerteis, and B. Krueger Plasmin in nephrotic urine activates the epithelial sodium channel J Am Soc Nephrol 20 2009 299 310
9. M. Nesovic, M. Stojanovic, M.M. Nesovic, J. Ciric, and M. Zarkovic Microalbuminuria is associated with salt sensitivity in hypertensive patients J Hum Hypertens 10 1996 573 576
10. A.P. Sappino, J. Huarte, J.D. Vassalli, and D. Belin Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney J Clin Invest 87 1991 962 970
11. C. Saha, G.J. Eckert, W.T. Ambrosius, T.Y. Chun, M.A. Wagner, and Q. Zhao Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension Hypertension 46 2005 481 487
12. J.D. Vassalli, and D. Belin Amiloride selectively inhibits the urokinase-type plasminogen activator FEBS Lett 214 1987 187 191
13. A.J. Smith, and R.N. Smith Kinetics and bioavailability of two formulations of amiloride in man Br J Pharmacol 48 1973 646 649
14. C.S. Oxlund, J.E. Henriksen, L. Tarnow, K. Schousboe, J. Gram, and I.A. Jacobsen Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial J Hypertens 31 2013 2094 2102
15. K.B. Buhl, C.S. Oxlund, U.G. Friis, P. Svenningsen, C. Bistrup, and I.A. Jacobsen Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro J Hypertens 32 2014 1672 1677
16. G.W. Yip, H.K. So, A.M. Li, B. Tomlinson, S.N. Wong, and R.Y. Sung Validation of A&D TM-2430 upper-arm blood pressure monitor for ambulatory blood pressure monitoring in children and adolescents, according to the British Hypertension Society protocol Blood Press Monit 17 2012 76 79
17. A.N. Rogoza, T.S. Pavlova, and M.V. Sergeeva Validation of A&D UA-767 device for the self-measurement of blood pressure Blood Press Monit 5 2000 227 231
18. B.S. Heran, J.M. Chen, J.J. Wang, and J.M. Wright Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension Cochrane Database Syst Rev 11 2012 CD008167
19. P. Svenningsen, U.G. Friis, J.B. Versland, K.B. Buhl, B. Moller Frederiksen, and H. Andersen Mechanisms of renal NaCl retention in proteinuric disease Acta Physiol (Oxf) 207 2013 536 545
20. G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, and M. Böhm 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension Blood Press 23 2014 3 16
21. D.A. Lane, S. Shah, and D.G. Beevers Low-dose spironolactone in the management of resistant hypertension: a surveillance study J Hypertens 25 2007 891 894
22. D.A. Lane, and D.G. Beevers Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent J Hypertens 25 2007 2515 2516
23. I.W. Park, S.S. Sheen, D. Yoon, S.H. Lee, G.T. Shin, and H. Kim Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring? J Clin Pharm Ther 39 2014 61 68
24. B. Zhang, S. Xie, W. Shi, and Y. Yang Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria Nephrol Dial Transplant 27 2012 1746 1755
25. F.A. Holtkamp, D. de Zeeuw, M.C. Thomas, M.E. Cooper, P.A. de Graeff, and H.J. Hillege An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function Kidney Int 80 2011 282 287
26. R.F. Andersen, K.B. Buhl, B.L. Jensen, P. Svenningsen, U.G. Friis, and B. Jespersen Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC Pediatr Nephrol 28 2013 1227 1234
27. D. Rotin, and L. Schild ENaC and its regulatory proteins as drug targets for blood pressure control Curr Drug Targets 9 2008 709 716
28. K. Tudpor, S. Lainez, A.J. Kwakernaak, N.V. Kovalevskaya, S. Verkaart, and S. van Genesen Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria J Am Soc Nephrol 23 2012 1824 1834
29. M.V. Cubellis, M.L. Nolli, G. Cassani, and F. Blasi Binding of single-chain prourokinase to the urokinase receptor of human U937 cells J Biol Chem 261 1986 15819 15822
30. P. Svenningsen, T.R. Uhrenholt, Y. Palarasah, K. Skjodt, B.L. Jensen, and O. Skott Prostasin-dependent activation of epithelial Na+ channels by low plasmin concentrations Am J Physiol Regul Integr Comp Physiol 297 2009 R1733 R1741
31. G. Hilal, J. Martel-Pelletier, J.P. Pelletier, N. Duval, and D. Lajeunesse Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts Arthritis Rheum 42 1999 2112 2122